Top

European Archives of Psychiatry and Clinical Neuroscience

Published in:

01-06-2012 | Original Paper

Longitudinal changes of fractional anisotropy in Alzheimer’s disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study

Authors: Y. Likitjaroen, T. Meindl, U. Friese, M. Wagner, K. Buerger, H. Hampel, S. J. Teipel

Published in: European Archives of Psychiatry and Clinical Neuroscience | Issue 4/2012

Abstract

Diffusion tensor imaging (DTI) demonstrates decline of fractional anisotropy (FA) as a marker of fiber tract integrity in Alzheimer’s disease (AD). We aimed to assess the longitudinal course of white matter microstructural changes in AD and healthy elderly control (HC) subjects and to evaluate the effects of treatment with the cholinesterase inhibitor galantamine on white matter microstructure in AD patients. We enrolled 28 AD patients and 11 healthy elderly control subjects (HC). AD patients were randomly assigned to 6-month double-blind galantamine treatment or placebo, with a 6-month open-label extension phase. DTI was performed at baseline, as well as at 6 and 12-month follow-up in AD patients. The HC subjects underwent DTI at baseline and 12-month follow-up without treatment. We measured FA in regions of interest covering the posterior cingulate and corpus callosum. At 6-month follow-up, the AD group showed significant FA decline in the left posterior cingulate. FA decline was significantly preserved in the posterior body of the corpus callosum in AD group with treatment compared to placebo. At 12-month follow-up, the AD patients showed no differences in FA decline between initial treatment and placebo groups after the 6-month open-label extension phase. A significant FA decline occurred in the left posterior cingulate across the AD and HC groups without between-group differences. DTI demonstrated FA decline in intracortically projecting fiber tracts in aging and AD over 1 year. Galantamine had limited impact on regional FA decline, which was not preserved after additional 6-month open-label treatment.

Barrick TR, Charlton RA, Clark CA, Markus HS (2010) White matter structural decline in normal ageing: a prospective longitudinal study using tract-based spatial statistics. NeuroImage 51:565–577PubMedCrossRef

Berres M, Monsch AU, Bernasconi F, Thalmann B, Stahelin HB (2000) Normal ranges of neuropsychological tests for the diagnosis of Alzheimer’s disease. Stud Health Technol Inform 77:195–199PubMed

Birks J (2006) Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev CD005593

Bokde AL, Karmann M, Teipel SJ, Born C, Lieb M, Reiser MF, Moller HJ, Hampel H (2009) Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study. J Clin Psychopharmacol 29:147–156PubMedCrossRef

Bozzali M, Falini A, Franceschi M, Cercignani M, Zuffi M, Scotti G, Comi G, Filippi M (2002) White matter damage in Alzheimer’s disease assessed in vivo using diffusion tensor magnetic resonance imaging. J Neurol Neurosurg Psychiatry 72:742–746PubMedCrossRef

Bozzali M, Franceschi M, Falini A, Pontesilli S, Cercignani M, Magnani G, Scotti G, Comi G, Filippi M (2001) Quantification of tissue damage in AD using diffusion tensor and magnetization transfer MRI. Neurology 57:1135–1137PubMedCrossRef

Braak H, Braak E (1997) Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18:351–357PubMedCrossRef

Brun A, Englund E (1986) A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 19:253–262PubMedCrossRef

Bugiani O, Constantinidis J, Ghetti B, Bouras C, Tagliavini F (1991) Asymmetrical cerebral atrophy in Alzheimer’s disease. Clin Neuropathol 10:55–60PubMed

10.

Choi SJ, Lim KO, Monteiro I, Reisberg B (2005) Diffusion tensor imaging of frontal white matter microstructure in early Alzheimer’s disease: a preliminary study. J Geriatr Psychiatry Neurol 18:12–19PubMedCrossRef

11.

Cortes F, Nourhashemi F, Guerin O, Cantet C, Gillette-Guyonnet S, Andrieu S, Ousset PJ, Vellas B (2008) Prognosis of Alzheimer’s disease today: a two-year prospective study in 686 patients from the REAL-FR Study. Alzheimers Dement 4:22–29PubMedCrossRef

12.

De Lacoste MC, Kirkpatrick JB, Ross ED (1985) Topography of the human corpus callosum. J Neuropathol Exp Neurol 44:578–591PubMedCrossRef

13.

Devine ME, Fonseca JA, Walker RW, Sikdar T, Stevens T, Walker Z (2007) Cerebral white matter changes and rate of progression of dementia during cholinesterase inhibitor treatment: a retrospective cohort study. Int J Geriatr Psychiatry 22:1120–1126PubMedCrossRef

14.

Di Patre PL, Read SL, Cummings JL, Tomiyasu U, Vartavarian LM, Secor DL, Vinters HV (1999) Progression of clinical deterioration and pathological changes in patients with Alzheimer disease evaluated at biopsy and autopsy. Arch Neurol 56:1254–1261PubMedCrossRef

15.

Fellgiebel A, Muller MJ, Wille P, Dellani PR, Scheurich A, Schmidt LG, Stoeter P (2005) Color-coded diffusion-tensor-imaging of posterior cingulate fiber tracts in mild cognitive impairment. Neurobiol Aging 26:1193–1198PubMedCrossRef

16.

Fillenbaum GG, Peterson B, Morris JC (1996) Estimating the validity of the clinical dementia rating scale: the CERAD experience. Consortium to establish a registry for alzheimer’s disease. Aging (Milano) 8:379–385

17.

Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRef

18.

Fox NC, Warrington EK, Freeborough PA, Hartikainen P, Kennedy AM, Stevens JM, Rossor MN (1996) Presymptomatic hippocampal atrophy in Alzheimer’s disease. A longitudinal MRI study. Brain 119(Pt 6):2001–2007PubMedCrossRef

19.

Griswold MA, Jakob PM, Heidemann RM, Nittka M, Jellus V, Wang J, Kiefer B, Haase A (2002) Generalized autocalibrating partially parallel acquisitions (GRAPPA). Magn Reson Med 47:1202–1210PubMedCrossRef

20.

Hashimoto M, Kazui H, Matsumoto K, Nakano Y, Yasuda M, Mori E (2005) Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer’s disease? Am J Psychiatry 162:676–682PubMedCrossRef

21.

Head D, Buckner RL, Shimony JS, Williams LE, Akbudak E, Conturo TE, McAvoy M, Morris JC, Snyder AZ (2004) Differential vulnerability of anterior white matter in nondemented aging with minimal acceleration in dementia of the Alzheimer type: evidence from diffusion tensor imaging. Cereb Cortex 14:410–423PubMedCrossRef

22.

Hensel A, Wolf H, Kruggel F, Riedel-Heller SG, Nikolaus C, Arendt T, Gertz HJ (2002) Morphometry of the corpus callosum in patients with questionable and mild dementia. J Neurol Neurosurg Psychiatry 73:59–61PubMedCrossRef

23.

Huang J, Friedland RP, Auchus AP (2007) Diffusion tensor imaging of normal-appearing white matter in mild cognitive impairment and early Alzheimer disease: preliminary evidence of axonal degeneration in the temporal lobe. AJNR Am J Neuroradiol 28:1943–1948PubMedCrossRef

24.

Jiang H, van Zijl PC, Kim J, Pearlson GD, Mori S (2006) DtiStudio: resource program for diffusion tensor computation and fiber bundle tracking. Comput Methods Programs Biomed 81:106–116PubMedCrossRef

25.

Jones DK, Catani M, Pierpaoli C, Reeves SJ, Shergill SS, O’Sullivan M, Golesworthy P, McGuire P, Horsfield MA, Simmons A, Williams SC, Howard RJ (2006) Age effects on diffusion tensor magnetic resonance imaging tractography measures of frontal cortex connections in schizophrenia. Hum Brain Mapp 27:230–238PubMedCrossRef

26.

Kabay SC, Gulbandilar E, Ozden H, Ozbag D, Guven G, Adapinar B, Durmaz R (2009) Evaluation of the size and area of the corpus callosum with the osiris method in alzheimer’s disease. Neurodegener Dis

27.

Kochunov P, Williamsin DE, Lancaster J, Fox P, Cornell J, Blangero J, Glahn DC (2010) Fractional anisotropy of water diffusion in cerebral white matter across the lifespan. Neurobiol Aging (in press)

28.

Le Bihan D (2003) Looking into the functional architecture of the brain with diffusion MRI. Nat Rev Neurosci 4:469–480PubMedCrossRef

29.

Leow AD, Yanovsky I, Parikshak N, Hua X, Lee S, Toga AW, Jack CR Jr, Bernstein MA, Britson PJ, Gunter JL, Ward CP, Borowski B, Shaw LM, Trojanowski JQ, Fleisher AS, Harvey D, Kornak J, Schuff N, Alexander GE, Weiner MW, Thompson PM (2009) Alzheimer’s disease neuroimaging initiative: a one-year follow up study using tensor-based morphometry correlating degenerative rates, biomarkers and cognition. Neuroimage 45:645–655PubMedCrossRef

30.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology 34:939–944PubMedCrossRef

31.

Medina D, DeToledo-Morrell L, Urresta F, Gabrieli JD, Moseley M, Fleischman D, Bennett DA, Leurgans S, Turner DA, Stebbins GT (2006) White matter changes in mild cognitive impairment and AD: a diffusion tensor imaging study. Neurobiol Aging 27:663–672PubMedCrossRef

32.

Mielke MM, Kozauer NA, Chan KC, George M, Toroney J, Zerrate M, Bandeen-Roche K, Wang MC, Vanzijl P, Pekar JJ, Mori S, Lyketsos CG, Albert M (2009) Regionally-specific diffusion tensor imaging in mild cognitive impairment and Alzheimer’s disease. Neuroimage 46:47–55PubMedCrossRef

33.

Morrison JH, Hof PR (2002) Selective vulnerability of corticocortical and hippocampal circuits in aging and Alzheimer’s disease. Prog Brain Res 136:467–486PubMedCrossRef

34.

Naggara O, Oppenheim C, Rieu D, Raoux N, Rodrigo S, Dalla Barba G, Meder JF (2006) Diffusion tensor imaging in early Alzheimer’s disease. Psychiatry Res 146:243–249PubMedCrossRef

35.

Nusbaum AO, Tang CY, Buchsbaum MS, Wei TC, Atlas SW (2001) Regional and global changes in cerebral diffusion with normal aging. AJNR Am J Neuroradiol 22:136–142PubMed

36.

Pantel J, Schroder J, Jauss M, Essig M, Minakaran R, Schonknecht P, Schneider G, Schad LR, Knopp MV (1999) Topography of callosal atrophy reflects distribution of regional cerebral volume reduction in Alzheimer’s disease. Psychiatry Res 90:181–192PubMedCrossRef

37.

Parente DB, Gasparetto EL, da Cruz LC Jr, Domingues RC, Baptista AC, Carvalho AC (2008) Potential role of diffusion tensor MRI in the differential diagnosis of mild cognitive impairment and Alzheimer’s disease. AJR Am J Roentgenol 190:1369–1374PubMedCrossRef

38.

Rose SE, Chen F, Chalk JB, Zelaya FO, Strugnell WE, Benson M, Semple J, Doddrell DM (2000) Loss of connectivity in Alzheimer’s disease: an evaluation of white matter tract integrity with colour coded MR diffusion tensor imaging. J Neurol Neurosurg Psychiatry 69:528–530PubMedCrossRef

39.

Salamon N, Sicotte N, Drain A, Frew A, Alger JR, Jen J, Perlman S, Salamon G (2007) White matter fiber tractography and color mapping of the normal human cerebellum with diffusion tensor imaging. J Neuroradiol 34:115–128PubMedCrossRef

40.

Scheltens P, Barkhof F, Leys D, Pruvo JP, Nauta JJ, Vermersch P, Steinling M, Valk J (1993) A semiquantative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J Neurol Sci 114:7–12PubMedCrossRef

41.

Scheltens P, Barkhof F, Leys D, Wolters EC, Ravid R, Kamphorst W (1995) Histopathologic correlates of white matter changes on MRI in Alzheimer’s disease and normal aging. Neurology 45:883–888PubMedCrossRef

42.

Sidaros A, Engberg AW, Sidaros K, Liptrot MG, Herning M, Petersen P, Paulson OB, Jernigan TL, Rostrup E (2008) Diffusion tensor imaging during recovery from severe traumatic brain injury and relation to clinical outcome: a longitudinal study. Brain 131:559–572PubMedCrossRef

43.

Stahl R, Dietrich O, Teipel S, Hampel H, Reiser MF, Schoenberg SO (2003) Assessment of axonal degeneration on Alzheimer’s disease with diffusion tensor MRI. Radiologe 43:566–575PubMedCrossRef

44.

Stahl R, Dietrich O, Teipel SJ, Hampel H, Reiser MF, Schoenberg SO (2007) White matter damage in Alzheimer disease and mild cognitive impairment: assessment with diffusion-tensor MR imaging and parallel imaging techniques. Radiology 243:483–492PubMedCrossRef

45.

Takahashi S, Yonezawa H, Takahashi J, Kudo M, Inoue T, Tohgi H (2002) Selective reduction of diffusion anisotropy in white matter of Alzheimer disease brains measured by 3.0 Tesla magnetic resonance imaging. Neurosci Lett 332:45–48PubMedCrossRef

46.

Teipel SJ, Bayer W, Alexander GE, Bokde AL, Zebuhr Y, Teichberg D, Muller-Spahn F, Schapiro MB, Moller HJ, Rapoport SI, Hampel H (2003) Regional pattern of hippocampus and corpus callosum atrophy in Alzheimer’s disease in relation to dementia severity: evidence for early neocortical degeneration. Neurobiol Aging 24:85–94PubMedCrossRef

47.

Teipel SJ, Bayer W, Alexander GE, Zebuhr Y, Teichberg D, Kulic L, Schapiro MB, Moller HJ, Rapoport SI, Hampel H (2002) Progression of corpus callosum atrophy in Alzheimer disease. Arch Neurol 59:243–248PubMedCrossRef

48.

Teipel SJ, Drzezga A, Bartenstein P, Moller HJ, Schwaiger M, Hampel H (2006) Effects of donepezil on cortical metabolic response to activation during (18) FDG-PET in Alzheimer’s disease: a double-blind cross-over trial. Psychopharmacology (Berl) 187:86–94CrossRef

49.

Teipel SJ, Flatz WH, Heinsen H, Bokde AL, Schoenberg SO, Stockel S, Dietrich O, Reiser MF, Moller HJ, Hampel H (2005) Measurement of basal forebrain atrophy in Alzheimer’s disease using MRI. Brain 128:2626–2644PubMedCrossRef

50.

Teipel SJ, Meindl T, Grinberg L, Heinsen H, Hampel H (2008) Novel MRI techniques in the assessment of dementia. Eur J Nucl Med Mol Imaging 35(Suppl 1):S58–S69PubMedCrossRef

51.

Tian J, Shi J, Bailey K, Mann DM (2004) Relationships between arteriosclerosis, cerebral amyloid angiopathy and myelin loss from cerebral cortical white matter in Alzheimer’s disease. Neuropathol Appl Neurobiol 30:46–56PubMedCrossRef

52.

Tune L, Tiseo PJ, Ieni J, Perdomo C, Pratt RD, Votaw JR, Jewart RD, Hoffman JM (2003) Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study. Am J Geriatr Psychiatry 11:169–177PubMed

53.

Venneri A, Shanks MF, Staff RT, Pestell SJ, Forbes KE, Gemmell HG, Murray AD (2002) Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer’s disease. Neuroreport 13:83–87PubMedCrossRef

54.

Wang PJ, Saykin AJ, Flashman LA, Wishart HA, Rabin LA, Santulli RB, McHugh TL, MacDonald JW, Mamourian AC (2006) Regionally specific atrophy of the corpus callosum in AD, MCI and cognitive complaints. Neurobiol Aging 27:1613–1617PubMedCrossRef

55.

Weaver KE, Richards TL, Liang O, Laurino MY, Samii A, Aylward EH (2009) Longitudinal diffusion tensor imaging in Huntington’s disease. Exp Neurol 216:525–529PubMedCrossRef

56.

Xie S, Xiao JX, Gong GL, Zang YF, Wang YH, Wu HK, Jiang XX (2006) Voxel-based detection of white matter abnormalities in mild Alzheimer disease. Neurology 66:1845–1849PubMedCrossRef

57.

Zhang Y, Schuff N, Jahng GH, Bayne W, Mori S, Schad L, Mueller S, Du AT, Kramer JH, Yaffe K, Chui H, Jagust WJ, Miller BL, Weiner MW (2007) Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology 68:13–19PubMedCrossRef

Title: Longitudinal changes of fractional anisotropy in Alzheimer’s disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study
Authors: Y. Likitjaroen
T. Meindl
U. Friese
M. Wagner
K. Buerger
H. Hampel
S. J. Teipel
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: European Archives of Psychiatry and Clinical Neuroscience / Issue 4/2012
Print ISSN: 0940-1334
Electronic ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-011-0234-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Longitudinal changes of fractional anisotropy in Alzheimer’s disease patients treated with galantamine: a 12-month randomized, placebo-controlled, double-blinded study

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Correlation with statistical significance and its explanation rate: comment on Minelli et al., “BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects.” (Eur Arch Psychiatry Clin Neurosci doi:10.1007/s00406-011-0189-3)

How close is evidence to truth in evidence-based treatment of mental disorders?

Influence of GRIA1, GRIA2 and GRIA4 polymorphisms on diagnosis and response to treatment in patients with major depressive disorder

Cholinergic blockade under working memory demands encountered by increased rehearsal strategies: evidence from fMRI in healthy subjects

Prevalence of the metabolic syndrome in unipolar major depression

White matter abnormalities and their impact on attentional performance in adult attention-deficit/hyperactivity disorder